Novel drugs combinations for improving survival from Acute Radiation Syndrome when administered 48h postirradiation

放射后 48 小时给药可提高急性放射综合症生存率的新型药物组合

基本信息

  • 批准号:
    9976446
  • 负责人:
  • 金额:
    $ 29.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-07-12 至 2021-12-31
  • 项目状态:
    已结题

项目摘要

Abstract. Bone marrow is one of the most radiation-sensitive tissues, and patients acutely exposed to total body irradiation (TBI) doses > 2 Gy develop severe neutropenia, thrombocytopenia, anemia, and lymphopenia within days to weeks of exposure, often dying from infections (due to a lack of neutrophils) and uncontrolled bleeding (insufficient platelets) (referred to as the hematopoietic acute radiation syndrome, or H-ARS). The few drugs that have received FDA approval to treat H-ARS increase survival when administered within 24h of radiation exposure, but do not increase survival when administered at later times such as 48h post-irradiation in animal H-ARS models. In a radiological/nuclear emergency, hundreds of thousands of people potentially will be exposed to > 2 Gy radiation and it is extremely unlikely that they all can be treated within the first 24 hours of radiation exposure. Thus, there is a critical unmet medical need for drugs capable of increasing survival from H-ARS when administered 48h or later post-irradiation. In a pilot study we identified a novel combination of 3 long-acting hematopoietic growth factor proteins that significantly improves 30-day survival of LD40/30 irradiated mice when administered once 48h post-TBI. This is the only drug/drug combination we are aware of capable of increasing survival when dosing is delayed until 48h post-TBI. When dosed once 24h post-TBI, the 3 proteins interact positively with each other to increase survival more than the individual proteins, most evident at high TBI doses (> 9 Gy). By combining the 3 proteins with a 4th radiation mitigator, an angiotensin converting enzyme inhibitor (ACEI), it is possible to obtain 100% 30-d survival of LD95/30 TBI mice, an unprecedented survival rate. This SBIR grant will build upon these exciting findings by (1) determining if the 3 protein combination (+/- the ACEI) can increase survival of mice exposed to higher LD70/30 and LD90/30 radiation doses when the proteins are administered 48h post-TBI; (2) determine whether all 3 proteins or only a subset of the proteins are required for increasing 30-d survival when dosed 48h post-TBI; (3) determine whether the 3 drug combination (+/- ACEI) can improve 30-d survival when administered at even later times post-TBI, e.g., 72h; and (4) perform a pharmacokinetic and mechanistic study of the 3 proteins and the ACEI in TBI mice to measure effective plasma levels of the 3 proteins and the ACEI over time, and to determine if increased 30d survival correlates with a more rapid increase in hematopoietic progenitor cell numbers early after irradiation in the mice. Additional mechanistic studies include performing complete blood cell analyses at various times post-TBI to determine if increased 30-d survival correlates with accelerated recovery of neutrophils, platelets, and other peripheral blood cell types. In addition, we will finalize GMP manufacturing processes and identify stable liquid formulations of the 3 proteins for use in future IND-enabling studies. These studies will lead to the development of a life-saving treatment option for a heretofore untreatable H-ARS population – patients who cannot be treated until 48h or later post-TBI.
摘要。骨髓是对辐射最敏感的组织之一,且患者急性总暴露

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

George Norbert Cox其他文献

George Norbert Cox的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('George Norbert Cox', 18)}}的其他基金

Stimulating innate immunity to protect against Ebola virus infection
刺激先天免疫力以预防埃博拉病毒感染
  • 批准号:
    10325941
  • 财政年份:
    2021
  • 资助金额:
    $ 29.35万
  • 项目类别:
Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation
放射后 48 小时给药可提高急性放射综合征生存率的新型药物组合
  • 批准号:
    10604184
  • 财政年份:
    2019
  • 资助金额:
    $ 29.35万
  • 项目类别:
Long-acting growth factors for treating the acute and long term effects of lethal
用于治疗致命性急性和长期影响的长效生长因子
  • 批准号:
    8840884
  • 财政年份:
    2013
  • 资助金额:
    $ 29.35万
  • 项目类别:
Long-Acting G-CSF Analog for Treating ARS
用于治疗 ARS 的长效 G-CSF 类似物
  • 批准号:
    8525060
  • 财政年份:
    2013
  • 资助金额:
    $ 29.35万
  • 项目类别:
Long-acting growth factors for treating the acute and long term effects of lethal
用于治疗致命性急性和长期影响的长效生长因子
  • 批准号:
    8573195
  • 财政年份:
    2013
  • 资助金额:
    $ 29.35万
  • 项目类别:
Long-acting growth factors for treating the acute and long term effects of lethal
用于治疗致命性急性和长期影响的长效生长因子
  • 批准号:
    8662198
  • 财政年份:
    2013
  • 资助金额:
    $ 29.35万
  • 项目类别:
Long-acting growth factors for treating the acute and long term effects of lethal
用于治疗致命性急性和长期影响的长效生长因子
  • 批准号:
    9264475
  • 财政年份:
    2013
  • 资助金额:
    $ 29.35万
  • 项目类别:
Long-Acting G-CSF Analog for Treating ARS
用于治疗 ARS 的长效 G-CSF 类似物
  • 批准号:
    8634011
  • 财政年份:
    2013
  • 资助金额:
    $ 29.35万
  • 项目类别:
Long-Acting IL-11 Analog for Treating Acute Radiation Syndrome
用于治疗急性放射综合症的长效 IL-11 类似物
  • 批准号:
    8049571
  • 财政年份:
    2010
  • 资助金额:
    $ 29.35万
  • 项目类别:
Long-Acting IL-11 Analog for Treating Acute Radiation Syndrome
用于治疗急性放射综合症的长效 IL-11 类似物
  • 批准号:
    7910657
  • 财政年份:
    2010
  • 资助金额:
    $ 29.35万
  • 项目类别:

相似国自然基金

基于构建骨骼类器官模型探究Fanconi anemia信号通路调控电刺激诱导神经化成骨过程的机制研究
  • 批准号:
    82302715
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
FANCM蛋白在传统Fanconi anemia通路以外对保护基因组稳定性的功能
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
范可尼贫血(Fanconi Anemia)基因FANCM在复制后修复中的作用及FA癌症抑制通路的机制研究
  • 批准号:
    31200592
  • 批准年份:
    2012
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Investigation of crosstalk between Fanconi Anemia pathway and ATM for novel therapeutic strategies of chemoresistant ALT-positive high-risk neuroblastoma
范可尼贫血通路与 ATM 之间的串扰研究,用于化疗耐药 ALT 阳性高危神经母细胞瘤的新治疗策略
  • 批准号:
    24K10442
  • 财政年份:
    2024
  • 资助金额:
    $ 29.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Immune escape mechanisms in BCOR/BCORL1 mutant hematopoietic stem cells from patients with aplastic anemia
再生障碍性贫血患者 BCOR/BCORL1 突变型造血干细胞的免疫逃逸机制
  • 批准号:
    23K15297
  • 财政年份:
    2023
  • 资助金额:
    $ 29.35万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Fanconi anemia経路に着目したiPS細胞における高レベル複製ストレスの原因解明
阐明 iPS 细胞中高水平复制应激的原因,重点关注范可尼贫血途径
  • 批准号:
    23K14452
  • 财政年份:
    2023
  • 资助金额:
    $ 29.35万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Analysis of the mechanism of hemolytic anemia in canine babesiosis and development of novel therapeutic measures
犬巴贝斯虫病溶血性贫血机制分析及新治疗措施开发
  • 批准号:
    23KJ0074
  • 财政年份:
    2023
  • 资助金额:
    $ 29.35万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Mobile phone-based screening for anemia in young children in western Kenya
基于手机的肯尼亚西部幼儿贫血筛查
  • 批准号:
    10752968
  • 财政年份:
    2023
  • 资助金额:
    $ 29.35万
  • 项目类别:
Brain blood flow, oxygenation, and cognition in adult onset iron deficiency anemia
成人缺铁性贫血的脑血流量、氧合和认知
  • 批准号:
    10735765
  • 财政年份:
    2023
  • 资助金额:
    $ 29.35万
  • 项目类别:
Chromatin State Alterations in Fanconi Anemia Hematologic Disease and Bone Marrow Failure
范可尼贫血血液疾病和骨髓衰竭中的染色质状态改变
  • 批准号:
    10735366
  • 财政年份:
    2023
  • 资助金额:
    $ 29.35万
  • 项目类别:
Accuracy and Feasibility of Non-Invasive Anemia Screening Assistant (ASIST) Device in Resource-Limited Settings
资源有限环境中非侵入性贫血筛查辅助 (ASIST) 设备的准确性和可行性
  • 批准号:
    10575222
  • 财政年份:
    2023
  • 资助金额:
    $ 29.35万
  • 项目类别:
Liver-Gut Axis in Neonatal Anemia and Its Role in RBC Transfusion Associated Gut Injury
新生儿贫血中的肝肠轴及其在红细胞输注相关肠道损伤中的作用
  • 批准号:
    10583807
  • 财政年份:
    2023
  • 资助金额:
    $ 29.35万
  • 项目类别:
A Sample-to-Answer Point-of-Care Diagnostic for Recently Transfused Sickle Cell Anemia Patients in Low Resource Settings
针对资源匮乏地区最近输血的镰状细胞性贫血患者的从样本到答案的护理点诊断
  • 批准号:
    10564553
  • 财政年份:
    2023
  • 资助金额:
    $ 29.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了